Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3061097 | 0.75 | TP53 (0.44) | ALDH1A1GAATSHRLMNAKDM4E | |
| SCHEMBL10802043 | 0.73 | TRPA1 (0.41) | ALDH1A1GAALMNAKDM4EMAPT | |
| SCHEMBL193631 | 0.71 | LMNA (0.50) | ALDH1A1GAATSHRLMNAKDM4E | |
| SCHEMBL11518630 | 0.71 | GAA (0.49) | ALDH1A1GAATSHRSMN1; SMN2CYP2D6 | |
| SCHEMBL3055365 | 0.68 | CYP1A2 (0.47) | ALDH1A1GAATSHRLMNAKDM4E | |
| SCHEMBL12002362 | 0.64 | S1PR1 (0.35) | — | |
| SCHEMBL12000503 | 0.63 | NPSR1 (0.38) | ALDH1A1GAALMNAKDM4EMAPT | |
| SCHEMBL3066648 | 0.63 | ALDH1A1 (0.60) | ALDH1A1LMNAKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL17755900 | 0.63 | APAF1 (0.40) | ALDH1A1TSHRLMNA | |
| SCHEMBL10984307 | 0.63 | ALDH1A1 (0.45) | ALDH1A1GAATSHRLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2010-10-14 | — | — | US | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | ALDH1A1 1930/4885GAA 203/4885TSHR 3338/4885 |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | ALDH1A1 1930/4885GAA 203/4885TSHR 3338/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | ALDH1A1 1930/4885GAA 203/4885TSHR 3338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.